/TCRR

TCRR Stock - TCR2 Therapeutics Inc.

Q: What is the analyst price target for TCRR?

Analyst price target information is not currently available for TCRR.

Q: What is TCRR's market cap?

Market capitalization information is not currently available for TCRR.

Healthcare|Biotechnology|NASDAQ

$1.48+0.00%

+$0.00 (+0.00%) • May 31

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+237.8%upside

Target: $5.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TCRR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.93

52W High$3.88

52W Low$0.82

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-153,499,000	$-99,742,000	$-68,700,000	$-51,382,000	$-26,453,000
Net Income	$-151,822,000	$-99,807,000	$-67,124,000	$-47,599,000	$-24,251,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-3.93	$-2.63	$-2.40	$-2.26	$-1.05

Company Overview

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit Website

Earnings History & Surprises

TCRR

Beat Rate

31%

Last 16 quarters

Avg Surprise

-8.4%

EPS vs Estimate

Beats / Misses

5/11

Last 12 quarters

Latest EPS

$-1.03

Q2 2023

EPS Surprise History

Q3 21

-6.7%

$-0.64vs$-0.60

Q4 21

-6.2%

$-0.69vs$-0.65

Q1 22

+4.0%

$-0.72vs$-0.75

Q2 22

-2.7%

$-0.76vs$-0.74

Q3 22

-6.5%

$-0.82vs$-0.77

Q4 22

+4.8%

$-0.79vs$-0.83

Q1 23

-95.0%

$-1.56vs$-0.80

Q2 23

-35.5%

$-1.03vs$-0.76

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 9, 2024	—	—	—	—
Q1 2024	Mar 21, 2024	—	—	—	—
Q4 2023	Nov 6, 2023	—	—	—	—
Q3 2023	Aug 14, 2023	$-0.81	—	—	—
Q2 2023	May 11, 2023	$-0.76	$-1.03	-35.5%	✗ MISS
Q1 2023	Mar 23, 2023	$-0.80	$-1.56	-95.0%	✗ MISS
Q4 2022	Nov 8, 2022	$-0.83	$-0.79	+4.8%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.77	$-0.82	-6.5%	✗ MISS
Q2 2022	May 12, 2022	$-0.74	$-0.76	-2.7%	✗ MISS
Q1 2022	Mar 22, 2022	$-0.75	$-0.72	+4.0%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.65	$-0.69	-6.2%	✗ MISS
Q3 2021	Aug 5, 2021	$-0.60	$-0.64	-6.7%	✗ MISS
Q2 2021	May 13, 2021	$-0.55	$-0.58	-5.5%	✗ MISS
Q1 2021	Mar 11, 2021	$-0.57	$-0.55	+3.5%	✓ BEAT
Q4 2020	Nov 12, 2020	$-0.52	$-0.56	-7.7%	✗ MISS
Q3 2020	Aug 12, 2020	$-0.61	$-0.67	-9.8%	✗ MISS
Q2 2020	May 14, 2020	$-0.60	$-0.65	-8.3%	✗ MISS
Q1 2020	Mar 30, 2020	$-0.67	$-0.54	+19.4%	✓ BEAT
Q4 2019	Nov 12, 2019	$-0.54	$-0.58	-7.4%	✗ MISS
Q3 2019	Aug 8, 2019	$-0.61	$-0.46	+24.6%	✓ BEAT

Frequently Asked Questions about TCRR

What is TCRR's current stock price?

TCR2 Therapeutics Inc. (TCRR) is currently trading at $1.48 per share. The stock has moved +0.00% today.

What is the analyst price target for TCRR?

The average analyst price target for TCRR is $5.00, based on 1 analyst.

What sector is TCR2 Therapeutics Inc. in?

TCR2 Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is TCRR's market cap?

TCR2 Therapeutics Inc. has a market capitalization of $0.06 billion, making it a small-cap company.

Does TCRR pay dividends?

No, TCR2 Therapeutics Inc. does not currently pay a dividend to shareholders.